Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
34,945,268
-
Shares change
-
+387,561
-
Total reported value, excl. options
-
$824,517,432
-
Value change
-
+$9,797,711
-
Number of buys
-
26
-
Number of sells
-
-29
-
Price
-
$23.83
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q2 2020
77 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2020.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,945,268 shares
of 54,711,345 outstanding shares and own 63.87% of the company stock.
Largest 10 shareholders include Apple Tree Partners IV, L.P. (16,786,713 shares), RTW INVESTMENTS, LP (3,544,248 shares), Redmile Group, LLC (2,502,306 shares), Cormorant Asset Management, LP (1,701,292 shares), GILDER GAGNON HOWE & CO LLC (1,569,564 shares), VANGUARD GROUP INC (1,278,341 shares), BlackRock Inc. (1,214,130 shares), RA CAPITAL MANAGEMENT, L.P. (1,119,963 shares), FEDERATED HERMES, INC. (830,400 shares), and FMR LLC (771,866 shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.